Efficacy and Safety of the Chinese Herbal Formula Granules in Chronic Kidney Disease Stage 3: A Prospective, Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial
- Conditions
- ephrology
- Registration Number
- ITMCTR1900002601
- Lead Sponsor
- Affiliated Hospital of Nanjing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Male and female patients diagnosed as primary CKD aged 18-75 years with estimated glomerular filtration rate (eGFR) >= 30 ml/min/1.73m2 and < 60 ml/min/1.73m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and 24-hour proteinuria <=2.0 g/d. Blood pressure was managed <=130/80 mmHg.
Patients with acute kidney injury, polycystic kidney disease, secondary kidney disease such as diabetic nephropathy were not recruited. Patients were receiving glucocorticoids, immunosuppressants and Tripterygium drug were excluded. Patients with concurrent serious disease, including primary cardiac, cerebral, pulmonary, hepatic, hematological, psychiatric disease, and pregnancy or lactation were also not included.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 24-hour Proteinuria;Urea Nitrogen;Adverse Events;eGFR;Serum Creatine;Serum Creatinine;blood routine examination;
- Secondary Outcome Measures
Name Time Method